CTOs on the Move

CODA Biotherapeutics

www.codabiotherapeutics.com

 
CODA Biotherapeutics` revolutionary chemogenetic platform aims to control the activity of cells to treat disease. With chemogenetics, the goal is to modify a target cell population using gene therapy to express a tunable `switch` protein. Cells modified with the `switch` can be activated or inactivated in a dose-dependent manner by a subsequently administered small molecule therapeutic, an effect that should only occur in the modified cells.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

CODA Biotherapeutics raised $19M on 10/03/2018
CODA Biotherapeutics raised $15M on 11/05/2019

Similar Companies

Bioporto

BioPorto s flagship product, The NGAL Test™, aids in the risk assessment of AKI in critically ill patients. CE marked for IVD use in select regions.

Metrohm USA Inc

Metrohm USA Inc is a Riverview, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

IFM Therapeutics

At IFM Therapeutics, LLC, we work to improve the lives of patients with inflammatory disorders and cancer by developing transformative medicines that precisely target the innate immune system, the body`s first line of immunological response and an essential component of immune function.

Green Scientific Labs

3DBio Therapeutics

3DBio is the first company implanting personalized 3D-printed living tissues in patients. #3DBioPrinting​ #3DBio